“Global Artificial Intelligence In Cardiology Market to reach a market value of USD 18.21 Billion by 2032 growing at a CAGR of 32.3%”
The Global Artificial Intelligence In Cardiology Market size is expected to reach $18.21 billion by 2032, rising at a market growth of 32.3% CAGR during the forecast period.
One of the key trends in hardware for AI in cardiology is the growing adoption of edge computing devices that can process data locally within hospital or clinical environments. This reduces latency and enhances data privacy—a critical factor in healthcare. Furthermore, specialized AI chips, such as neural processing units (NPUs), are being incorporated into medical imaging systems and diagnostic devices to support real-time cardiac assessments.
The major strategies followed by the market participants are Product Launches as the key developmental strategy to keep pace with the changing demands of end users. For instance, In April, 2025, Tempus AI, Inc. unveiled a multi-center study titled “Electrocardiogram-based Artificial Intelligence-Assisted Detection of Heart Disease” (ECG-AID), focusing on evaluating the impact of AI-enabled predictive tests in cardiology . These efforts demonstrate Tempus' commitment to leveraging AI in the cardiology sector. Additionally, In April, 2025, Viz.ai, Inc. unveiled Viz 3D CTA, an AI-powered imaging solution designed to enhance 3D visualization of CT angiography. The technology improves diagnostic accuracy and speeds up clinical decision-making, especially in cardiology and stroke care, supporting faster interventions and improved patient outcomes through advanced artificial intelligence and automated workflows.
Based on the Analysis presented in the KBV Cardinal matrix; GE HealthCare Technologies, Inc. is the forerunner in the Artificial Intelligence In Cardiology Market. In March, 2025, GE HealthCare Technologies, Inc. unveiled the Revolution Vibe CT system, featuring Unlimited One-Beat cardiac imaging and advanced AI-powered solutions. Designed to enhance diagnostic accuracy and workflow efficiency, the system delivers high-quality images in a single heartbeat. It aims to improve patient outcomes and streamline operations in clinical environments. Companies such as Viz.ai, Inc., Tempus AI, Inc., and Koninklijke Philips N.V., and are some of the key innovators in Artificial Intelligence In Cardiology Market.
The COVID-19 pandemic had a transformative impact on the Artificial Intelligence (AI) in cardiology market, driving advancements and adoption in several positive ways. Below are key impacts described in past tense, focusing on general trends and developments without relying on market research data: The pandemic spurred widespread use of AI in cardiology by emphasizing the need for remote healthcare solutions. Thus, the COVID-19 pandemic had a positive impact on the market.
Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide. Factors such as aging populations, sedentary lifestyles, poor diets, smoking, and rising incidences of diabetes and hypertension have significantly escalated the prevalence of CVDs. This growing disease burden places immense pressure on healthcare systems to provide timely and accurate diagnoses and effective management to reduce complications and mortality. Thus, the rising incidence of cardiovascular diseases coupled with the critical need for early and accurate diagnosis represents a fundamental driver for the growth of AI in cardiology, positioning these technologies as essential tools in combating the global cardiac health crisis.
Additionally, the rapid evolution of medical imaging technologies and data analytics capabilities has been a key driver propelling AI integration into cardiology. Modern cardiovascular imaging techniques—such as echocardiography, cardiac magnetic resonance imaging (MRI), computed tomography (CT), and nuclear imaging—generate highly detailed and voluminous datasets. Interpreting this data accurately requires specialized expertise and significant time investment. Therefore, advancements in medical imaging and data analytics technologies serve as a powerful catalyst accelerating the adoption and effectiveness of AI solutions within cardiology, ultimately transforming cardiac care delivery.
One of the most significant restraints impeding the widespread adoption of artificial intelligence in cardiology is the growing concern over data privacy and security. Cardiovascular AI applications depend heavily on collecting, storing, and analyzing vast amounts of sensitive patient health data, including personal identifiers, medical histories, imaging scans, and real-time monitoring data. This enormous volume of data, often aggregated from multiple sources such as hospitals, wearable devices, and mobile applications, presents a lucrative target for cybercriminals. Thus, data privacy and security concerns act as a critical restraint on the market, necessitating stringent safeguards and ethical standards to foster patient trust and safe AI deployment.
The value chain analysis of the Artificial Intelligence in Cardiology Market highlights a comprehensive flow from Research and Development to End-User Adoption. It begins with foundational R&D Activities, followed by Data Acquisition & Management, essential for training AI models. The process moves into Model Development & Training, leading to Regulatory Approvals and Certifications. Once approved, Product Integration & Deployment take place within healthcare systems. Marketing and Sales Driving adoption through targeted promotion. After-Sales Support & Feedback Loop Enhancing solutions via continuous feedback.
The leading players in the market are competing with diverse innovative offerings to remain competitive in the market. The above illustration shows the percentage of revenue shared by some of the leading companies in the market. The leading players of the market are adopting various strategies in order to cater demand coming from the different industries. The key developmental strategies in the market are Product Launches and Product Expansions.
Free Valuable Insights: Global Artificial Intelligence In Cardiology Market size to reach USD 18.21 Billion by 2032
Based on component, the market is characterized into hardware, software, and services. The software segment garnered 34% revenue share in the market in 2024. This segment includes a wide range of AI-enabled software platforms designed to assist cardiologists in clinical decision-making, predictive analysis, image interpretation, and patient risk assessment. AI software in cardiology often incorporates machine learning algorithms, deep learning frameworks, and natural language processing tools to analyze echocardiograms, CT scans, ECG data, and electronic health records.
By medical condition, the market is divided into ischemic heart disease /CAD, cardiac arrhythmias, heart failure, and others. The cardiac arrhythmias segment garnered 20% revenue share in the market in 2024. AI tools are being used extensively to detect and monitor irregular heart rhythms, such as atrial fibrillation, which often go unnoticed in their early stages. By analyzing ECG data and wearable device outputs, AI algorithms can identify abnormal patterns and notify healthcare providers in real time.
On the basis of application, the market is classified into diagnosis, prediction, drug discovery, and others. The prediction segment recorded 29% revenue share in the market in 2024. This segment encompasses AI tools used to forecast potential cardiac events and patient outcomes based on historical data, genetic information, lifestyle factors, and continuous monitoring inputs. Predictive analytics powered by machine learning models help healthcare professionals assess the risk of conditions such as heart attacks, strokes, and heart failure, allowing for preemptive interventions and personalized care strategies.
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded 43% revenue share in the market in 2024. This growth is primarily attributed to the presence of advanced healthcare infrastructure, a high concentration of AI and healthcare technology companies, and strong investments in digital health initiatives. The United States, in particular, has been at the forefront of AI integration in cardiology, leveraging technologies such as machine learning, deep learning, and predictive analytics to improve cardiovascular diagnostics, treatment planning, and patient monitoring.
The competition in the Artificial Intelligence in Cardiology market is high. Numerous emerging companies and research-based startups are aggressively innovating in areas like ECG analysis, cardiac imaging, and predictive analytics. With increasing demand for precision cardiology, these players compete fiercely for clinical validation, AI breakthroughs, strategic partnerships, and regulatory clearances to establish a strong market foothold.
| Report Attribute | Details |
|---|---|
| Market size value in 2024 | USD 2.02 Billion |
| Market size forecast in 2032 | USD 18.21 Billion |
| Base Year | 2024 |
| Historical Period | 2021 to 2023 |
| Forecast Period | 2025 to 2032 |
| Revenue Growth Rate | CAGR of 32.3% from 2025 to 2032 |
| Number of Pages | 311 |
| Number of Tables | 374 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Market Share Analysis, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
| Segments covered | Component, Application, Medical Condition, Region |
| Country scope |
|
| Companies Included | IDOVEN S.L., Ultromics Ltd., CardiAI.Inc., Tempus AI, Inc., Koninklijke Philips N.V., Cleerly, Inc., Vista AI, Inc., Viz.ai, Inc., RSIP Vision Ltd., and GE HealthCare Technologies, Inc. |
By Component
By Application
By Medical Condition
By Geography
This Market size is expected to reach $18.21 billion by 2032.
Advancements in Medical Imaging and Data Analytics Technologies are driving the Market in coming years, however, Data Privacy and Security Concerns restraints the growth of the Market.
IDOVEN S.L., Ultromics Ltd., CardiAI.Inc., Tempus AI, Inc., Koninklijke Philips N.V., Cleerly, Inc., Vista AI, Inc., Viz.ai, Inc., RSIP Vision Ltd., and GE HealthCare Technologies, Inc.
The expected CAGR of this Market is 32.3% from 2023 to 2032.
The Diagnosis segment led the maximum revenue in the Market by Application in 2024, thereby, achieving a market value of $7.03 billion by 2032.
The North America region dominated the Market by Region in 2024, thereby, achieving a market value of $7.56 billion by 2032.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 